IN2014MN02492A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02492A
IN2014MN02492A IN2492MUN2014A IN2014MN02492A IN 2014MN02492 A IN2014MN02492 A IN 2014MN02492A IN 2492MUN2014 A IN2492MUN2014 A IN 2492MUN2014A IN 2014MN02492 A IN2014MN02492 A IN 2014MN02492A
Authority
IN
India
Prior art keywords
combination therapy
stimulator
cdn
sting
recruitment
Prior art date
Application number
Inventor
Thomas W Dubensky
Meredith Lia Ling Leong
Drew M Pardoll
Young Jun Kim
Original Assignee
Aduro Biotech
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech, Univ Johns Hopkins filed Critical Aduro Biotech
Publication of IN2014MN02492A publication Critical patent/IN2014MN02492A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides a combination therapy which relies on a small molecule immune stimulator cyclic di nucleotide (CDN) that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes) formulated with allogeneic human tumor cell lines engineered to secrete high amounts of GM CSF. This combination therapy can provide an ideal synergy of multiple tumor associated antigens DC recruitment and proliferation coupled with a potent DC activation stimulus.
IN2492MUN2014 2012-06-08 2013-06-07 IN2014MN02492A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657574P 2012-06-08 2012-06-08
PCT/US2013/044744 WO2013185052A1 (en) 2012-06-08 2013-06-07 Compostions and methods for cancer immunotherapy

Publications (1)

Publication Number Publication Date
IN2014MN02492A true IN2014MN02492A (en) 2015-07-17

Family

ID=49712686

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2492MUN2014 IN2014MN02492A (en) 2012-06-08 2013-06-07

Country Status (11)

Country Link
US (1) US9770467B2 (en)
EP (1) EP2858722B8 (en)
JP (1) JP6257607B2 (en)
KR (1) KR20150022996A (en)
CN (1) CN104507538B (en)
AU (1) AU2013271375B2 (en)
CA (1) CA2876150A1 (en)
IN (1) IN2014MN02492A (en)
NZ (1) NZ702392A (en)
SG (2) SG10201610251PA (en)
WO (1) WO2013185052A1 (en)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6257607B2 (en) 2012-06-08 2018-01-10 アデュロ バイオテック，インコーポレイテッド Compositions and methods for cancer immunotherapy
MX361680B (en) 2012-12-13 2018-12-13 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use.
EP3398616A3 (en) 2012-12-19 2019-01-30 Board of Regents, The University of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
SG10201708821RA (en) 2013-04-29 2017-12-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
JP2016518140A (en) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Cyclic dinucleotide derivatization of type I interferon
JP6400082B2 (en) * 2013-05-18 2018-10-03 アデュロ バイオテック，インコーポレイテッド Compositions and methods for inhibiting "stimulating factor of interferon gene" dependent signaling
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
ES2754269T3 (en) 2013-05-18 2020-04-16 Aduro Biotech Inc Compositions and Activation Methods of "Interferon Gene Stimulator-dependent" Signaling
JP2016526532A (en) * 2013-06-14 2016-09-05 インターベット インターナショナル ベー． フェー． Pharmaceutical composition comprising GpG oligodeoxynucleotide and cyclic di-GMP
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
GEP20237479B (en) 2013-10-18 2023-03-27 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015108595A1 (en) * 2014-01-15 2015-07-23 Nikolai Khodarev Anti-tumor therapy
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
CN103908468B (en) 2014-04-21 2017-02-08 上海捌加壹医药科技有限公司 Application of cyclic dinucleotide cGAMP in preparing anti-tumor medicaments
CR20160564A (en) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd CYCLIC DINUCLEOTIDES AS STING MODULATORS
EP3191095A2 (en) * 2014-09-08 2017-07-19 Dana Farber Cancer Institute, Inc. Methods of treating cancer comprising administering a ppar-gamma agonist
US10010607B2 (en) 2014-09-16 2018-07-03 Institut Curie Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response
JP7305300B2 (en) * 2014-11-05 2023-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Combination immunotherapy
WO2016079899A1 (en) 2014-11-20 2016-05-26 国立研究開発法人医薬基盤・健康・栄養研究所 NOVEL Th1-INDUCING ADJUVANT COMPRISING COMBINATION OF DIFFERENT NUCLEIC ACID ADJUVANTS, AND USE OF SAME
EP3233191A1 (en) * 2014-12-16 2017-10-25 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
CN107148424B (en) * 2014-12-16 2021-01-08 凯拉治疗股份公司 Cyclic dinucleotides for inducing cytokines
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
CA3013713C (en) 2015-02-11 2025-09-09 The Johns Hopkins University Bacteria over-expressing c-di-amp and therapeutic methods
EP3291821B1 (en) * 2015-05-07 2026-02-25 Baylor College of Medicine Dendritic cell immunotherapy
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
MA42608A (en) 2015-08-13 2018-06-20 Merck Sharp & Dohme CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS (INTERFERON GENE STIMULATOR)
CN106540255A (en) * 2015-09-18 2017-03-29 聊城市奥润生物医药科技有限公司 Ring dinucleotide cGAMP combines application of the Avastin in antitumor
CN106540254A (en) * 2015-09-22 2017-03-29 聊城市奥润生物医药科技有限公司 Ring dinucleotide cGAMP and its derivant are potential immunological adjuvants
CN106540253A (en) * 2015-09-24 2017-03-29 聊城市奥润生物医药科技有限公司 The application of cGAMP and its derivant in anti-tumor vaccine is prepared
CN105367617A (en) * 2015-09-25 2016-03-02 武汉品生科技有限公司 Derivative based on c-di-AMP, tat polypeptide and application of derivative in inhibitor in type I interferon micromolecules
CA3006930A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
KR20250049441A (en) 2016-01-11 2025-04-11 인네이트 튜머 이뮤니티, 인코포레이티드 Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
CN106544319A (en) * 2016-01-24 2017-03-29 聊城市奥润生物医药科技有限公司 A kind of compositionss for stimulating maturing dendritic cell and its method for stimulating maturing dendritic cell
CN108779473A (en) 2016-03-16 2018-11-09 法国居里学院 It is used to prepare the purposes of the method and the particle of the virion with ring dinucleotides for treating cancer
EP3429596B1 (en) * 2016-03-18 2022-08-31 Immune Sensor, LLC Cyclic di-nucleotide compounds and methods of use
ES2781474T3 (en) 2016-04-07 2020-09-02 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
PE20181884A1 (en) 2016-04-07 2018-12-07 Glaxosmithkline Ip Dev Ltd USEFUL HETEROCYCLIC AMIDES AS PROTEIN MODULATORS
WO2017186711A1 (en) 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
KR102569881B1 (en) 2016-07-06 2023-08-22 에프-스타 테라퓨틱스 인코포레이티드 Compounds, compositions and methods for treating disease
DK3922279T3 (en) 2016-08-30 2025-02-03 Dana Farber Cancer Inst Inc DRUG DELIVERY PREPARATIONS AND THEIR USE
EA037513B1 (en) * 2016-09-17 2021-04-06 ИММЬЮН СЕНСОР, ЭлЭлСи Cyclic dinucleotide compounds and methods of use thereof
RS62410B1 (en) 2016-10-04 2021-10-29 Merck Sharp & Dohme Benzo[b]thiophene compounds as sting agonists
JOP20170192A1 (en) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co Cyclic dinucleotide
KR101889181B1 (en) * 2016-12-19 2018-08-16 주식회사 포스코 High-strength steel having excellent bendability and stretch-flangeability and method for manufacturing same
WO2018119325A1 (en) * 2016-12-22 2018-06-28 Mavupharma, Inc. Compositions and methods of enhancing or augmenting type i ifn production
WO2018144775A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
US20200055883A1 (en) * 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
WO2018156625A1 (en) 2017-02-21 2018-08-30 Board Of Regents,The University Of Texas System Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
UY37695A (en) 2017-04-28 2018-11-30 Novartis Ag BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
KR20200028392A (en) * 2017-06-12 2020-03-16 유니버시티 오브 마이애미 STING-dependent activator for the treatment of diseases
US11969499B2 (en) 2017-06-16 2024-04-30 William Marsh Rice University Hydrogel delivery of sting immunotherapy for treatment cancer
JP2020530838A (en) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Benzo [b] thiophene STING agonist for cancer treatment
WO2019027857A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND BENZO[b]THIOPHENE STING AGONISTS FOR CANCER TREATMENT
WO2019046511A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
CN111417630B (en) 2017-10-05 2023-06-06 葛兰素史克知识产权开发有限公司 Modulator of Stimulator of Interferon Genes (STING)
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
CN107619438B (en) * 2017-10-11 2021-12-03 广州云启科技有限公司 Novel cyclic dinucleotide receptor and method and kit for screening agonist or inhibitor thereof
CN109694397B (en) * 2017-10-23 2021-08-31 上海弘翊生物科技有限公司 Cyclic dinucleotide compounds, preparation method and application thereof
MX2020004858A (en) 2017-11-10 2020-10-01 Takeda Pharmaceuticals Co Sting modulator compounds, and methods of making and using.
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111511754B (en) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 2’3’ cyclic dinucleotide with phosphonate bond that activates STING adapter protein
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
TW202003032A (en) 2018-03-23 2020-01-16 美商科迪亞克生物科學公司 Extracellular vesicle comprising STING-agonist
WO2019195124A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Benzothiophenes and related compounds as sting agonists
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
TW202005654A (en) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2'2'-cyclic dinucleotides
TWI833744B (en) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-cyclic dinucleotides
TWI818007B (en) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-cyclic dinucleotides
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
US12291548B2 (en) 2018-07-10 2025-05-06 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2020036199A1 (en) 2018-08-16 2020-02-20 Eisai R&D Management Co., Ltd. Salts of compounds and crystals thereof
MA53438A (en) 2018-08-24 2021-09-15 Codiak Biosciences Inc EXTRACELLULAR VESICLES TARGETING DENDRITIC CELLS AND USES THEREOF
WO2020093040A1 (en) * 2018-11-02 2020-05-07 The Regents Of The University Of California Methods to diagnose and treat cancer using non-human nucleic acids
CA3129011C (en) 2019-03-07 2023-12-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
US20240108747A1 (en) 2019-03-21 2024-04-04 Lonza Sales Ag Extracellular vesicle conjugates and uses thereof
BR112021018694A2 (en) 2019-03-21 2021-11-30 Codiak Biosciences Inc Extracellular vesicles for vaccine delivery
TW202104214A (en) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 Chemical compounds
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
WO2021003445A1 (en) 2019-07-03 2021-01-07 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021035257A1 (en) * 2019-08-21 2021-02-25 The Scripps Research Institute Monocyclic agonists of stimulator of interferon genes sting
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
JP2022551420A (en) 2019-09-25 2022-12-09 コディアック バイオサイエンシーズ， インコーポレイテッド Combining IL-12-presenting exosomes with STING agonist-containing exosomes to treat tumors
US20230241089A1 (en) 2019-09-25 2023-08-03 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
EP4034081A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Extracellular vesicle compositions
EP4034276A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Methods of producing extracellular vesicles
CN114981265B (en) 2019-12-18 2025-01-03 Ctxt私人有限公司 Compound
EP4075980B1 (en) 2019-12-18 2025-07-23 Stinginn LLC Substituted 1,2, 4-triazoles and methods of use
US12251449B2 (en) 2019-12-19 2025-03-18 William Marsh Rice University Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
US20230114434A1 (en) 2020-03-13 2023-04-13 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
AU2021236763A1 (en) 2020-03-20 2022-10-06 Lonza Sales Ag Extracellular vesicles for therapy
AU2021257050A1 (en) * 2020-04-15 2022-10-27 Statens Serum Institut Liposomal composition for preventing or early treatment of pathogenic infection
US20230149560A1 (en) 2020-04-20 2023-05-18 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
JP7072604B2 (en) * 2020-06-23 2022-05-20 アンスティテュ・クリー Methods for Preparing Viral Particles Containing Cyclic Dinucleotides and Use of Said Particles to Treat Cancer
CN111956797B (en) * 2020-07-10 2022-05-13 清华大学 Novel vaccine adjuvant and application thereof in new coronary pneumonia vaccine and other vaccines
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
EP4216993A2 (en) 2020-09-23 2023-08-02 Codiak BioSciences, Inc. Methods of producing extracellular vesicles
EP4240488A1 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Antibody drug conjugates
WO2022118043A1 (en) * 2020-12-03 2022-06-09 Enara Bio Limited Novel protein-ligand complex
JP2024514707A (en) 2021-04-20 2024-04-02 アンスティテュ・クリー Compositions and methods for use in immunotherapy
EP4326321A1 (en) 2021-04-20 2024-02-28 Institut Curie Compositions and methods for use in immunotherapy
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
WO2024086799A2 (en) * 2022-10-20 2024-04-25 Northwestern University Lipid nanoparticles and methods of using the same for treating cell proliferative diseases and disorders
CN118671349A (en) * 2024-05-10 2024-09-20 浙江省肿瘤医院 High-throughput screening method of anti-gastric cancer drugs

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9110808D0 (en) 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
IT1262895B (en) 1992-03-02 1996-07-22 Protein extracted from cytotoxic strains of Helicobacter pylori, gene expressing it, use of the protein as a vaccine or for diagnostic purposes.
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US6033674A (en) 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
AU741602B2 (en) 1998-02-02 2001-12-06 Johns Hopkins University School Of Medicine, The A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
ATE299885T1 (en) 1999-02-15 2005-08-15 Nippon Shinyaku Co Ltd SHORT CHAIN POLYNUCLEOTIDES AND METHOD FOR THE PRODUCTION THEREOF
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
ATE324888T1 (en) 1999-06-14 2006-06-15 Cancer Rec Tech Ltd CANCER THERAPY
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
WO2002024739A2 (en) 2000-09-21 2002-03-28 The Regents Of The University Of California Spas-1 cancer antigen
WO2002059575A2 (en) 2001-01-23 2002-08-01 The Trustees Of Princeton University, Princeton University Method and apparatus for analysis of biological solutions
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
CA2533873A1 (en) 2003-07-28 2005-04-07 David K.R. Karaolis Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
EP1682173A4 (en) 2003-10-15 2007-10-31 Medimmune Inc EPHA2 VACCINES BASED ON LISTERIA
EP1677765A1 (en) 2003-10-24 2006-07-12 Alza Corporation Preparation of lipid particles
US7592326B2 (en) * 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
JP4887284B2 (en) 2004-03-15 2012-02-29 デイビッド・ケイ・アール・カラオリス Methods for inhibiting the growth of cancer cells or increasing apoptosis of cancer cells
WO2006124340A2 (en) 2005-05-06 2006-11-23 The Regents Of California University Microfluidic system for identifying or sizing individual particles passing through a channel
US20070059683A1 (en) 2005-09-15 2007-03-15 Tom Barber Veterinary diagnostic system
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
WO2007064945A2 (en) 2005-12-01 2007-06-07 Pronai Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
AU2007292302A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing PARP inhibitors and uses thereof
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
WO2013166000A1 (en) 2012-04-30 2013-11-07 Barber Glen N Modulating immune responses
EP2324044A4 (en) 2008-08-04 2012-04-25 Univ Miami STING (INTERFERON GENE STIMULATOR), A REGULATOR OF INDIAN IMMUNE RESPONSES
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
MY160201A (en) 2008-12-09 2017-02-28 Coley Pharm Group Inc Immunostimulatory oligonucleotides
WO2010104883A1 (en) 2009-03-09 2010-09-16 Molecular Express, Inc. Methods and compositions for liposomal formulation of antigens and uses thereof
US8414630B2 (en) 2009-03-10 2013-04-09 Marc Evan Richelsoph Active bone screw
HUE031051T2 (en) 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
WO2011003025A1 (en) 2009-07-01 2011-01-06 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
US8771933B2 (en) 2009-10-06 2014-07-08 Massachusetts Institute Of Technology Continuous-flow deformability-based cell separation
US20110287948A1 (en) 2010-03-22 2011-11-24 Massachusetts Institute Of Technology Measurement of material properties and related methods and compositions based on cytoadherence
JP6042802B2 (en) 2010-04-27 2016-12-14 ザ・ジョンズ・ホプキンス・ユニバーシティ Immunogenic compositions and methods for treating neoplasms (tumors).
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
SI2640842T1 (en) 2010-11-17 2018-09-28 Aduro Biotech, Inc. Methods and compositions for inducing an immune response to egfrviii
US9061048B2 (en) 2010-12-15 2015-06-23 The Regents Of The University Of California Cyclic di-AMP induction of type I interferon
EP2655392B1 (en) 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
EP2697357A4 (en) 2011-04-15 2015-04-22 Univ British Columbia METHOD AND APPARATUS FOR PARTICLE SEPARATION
WO2013086331A1 (en) 2011-12-07 2013-06-13 President And Fellows Of Harvard College High efficiency di-nucleotide cyclase
JP6257607B2 (en) 2012-06-08 2018-01-10 アデュロ バイオテック，インコーポレイテッド Compositions and methods for cancer immunotherapy
US9090646B2 (en) 2012-12-05 2015-07-28 Rutgers, The State University Of New Jersey Biotinylated compounds
MX361680B (en) 2012-12-13 2018-12-13 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use.
EP3398616A3 (en) 2012-12-19 2019-01-30 Board of Regents, The University of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
SG10201708821RA (en) 2013-04-29 2017-12-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
JP2016518140A (en) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Cyclic dinucleotide derivatization of type I interferon
JP6400082B2 (en) 2013-05-18 2018-10-03 アデュロ バイオテック，インコーポレイテッド Compositions and methods for inhibiting "stimulating factor of interferon gene" dependent signaling
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
ES2754269T3 (en) 2013-05-18 2020-04-16 Aduro Biotech Inc Compositions and Activation Methods of "Interferon Gene Stimulator-dependent" Signaling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators

Also Published As

Publication number Publication date
SG10201610251PA (en) 2017-01-27
JP2015518901A (en) 2015-07-06
KR20150022996A (en) 2015-03-04
WO2013185052A1 (en) 2013-12-12
EP2858722B1 (en) 2017-12-13
AU2013271375B2 (en) 2018-03-22
SG11201407875UA (en) 2014-12-30
JP6257607B2 (en) 2018-01-10
CA2876150A1 (en) 2013-12-12
NZ702392A (en) 2017-03-31
CN104507538B (en) 2018-04-06
AU2013271375A1 (en) 2014-12-18
EP2858722A4 (en) 2015-12-23
EP2858722A1 (en) 2015-04-15
CN104507538A (en) 2015-04-08
US9770467B2 (en) 2017-09-26
US20150010613A1 (en) 2015-01-08
EP2858722B8 (en) 2018-02-21
HK1204302A1 (en) 2015-11-13

Similar Documents

Publication Publication Date Title
IN2014MN02492A (en)
PH12015502438B1 (en) Compositions and methods for activating ``stimulator of interferon gene``-dependent signalling
UY36969A (en) COMPOSITIONS AND METHODS TO ACTIVATE THE DEPENDENT SIGNALING OF THE INTERFERON GEN STIMULATOR
CO2017009104A2 (en) Dinucleotide derivatives of bis-2’-fluoro-bis-3’-5’-cyclic purine
MX2015007447A (en) Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use.
MX2022003323A (en) Central nervous system targeting polynucleotides.
MX2018004755A (en) Delivery of central nervous system targeting polynucleotides.
NZ744821A (en) Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
MX2015002292A (en) Methods for treating or preventing asthma by administering an il-4r antagonist.
MX384192B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MY176022A (en) Acylated glucagon analogues
MY174248A (en) Targeted/immunomodulatory fusion proteins and methods for making same
MX2020010991A (en) Composition for controlled ovarian stimulation.
MX370567B (en) Treatment of myelosuppression.
GEP20176804B (en) Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same
MX2017006437A (en) Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain.
MX2018000419A (en) Substituted amide derivatives having multimodal activity against pain.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2016006603A (en) Piperidine compounds having multimodal activity against pain.
HK1211239A1 (en) Treatment regimens
TN2015000408A1 (en) Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
MX2019009243A (en) Methods for treating or preventing asthma by administering an il-4r antagonist.
TH173657A (en) Composition and methods for stimulating signaling dependent on interferon genes.